177 - lutetium PNT 2001 - POINT Biopharma
Alternative Names: 177Lu-PNT2001; PNT-2001 Lu-177 isotope; PNT-2001 lutetium 177 isotopeLatest Information Update: 28 Apr 2025
At a glance
- Originator Scintomics
- Developer POINT Biopharma
- Class Amides; Antineoplastics; Radiopharmaceuticals
- Mechanism of Action Ionising radiation emitters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Prostate cancer
Most Recent Events
- 28 Apr 2025 No recent reports of development identified for preclinical development in Prostate-cancer in USA (Parenteral)
- 27 Dec 2023 POINT Biopharma has been acquired by Eli Lilly and Company
- 04 Jan 2022 177 - lutetium PNT 2001 is available for licensing as of 04 Jan 2022. https://www.pointbiopharma.com/contact-us